In addition, Bevacizumab, a humanised mouse anti-human VEGF antibody, could inhibit the CRC m-CTCs survival mediated by VEGF (Fig. 4i) and block the LSS-induced ATOH8 and HK2 upregulation (Fig. 4j), implying the ATOH8 upregulation induced by LSS is related to the secretion of VEGF. This evidence concerns the gene ATOH8 and colorectal carcinoma.